Mylan (NYSE:MYL) shares are trading lower by $2.73 at $35.51 in Tuesday's session.
The catalyst for the decline is a report that attorney generals from 46 states will expand a suit related to alleged price fixing among generic drug-makers to 18 companies involving 15 different medicines.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
After a flat open, Mylan found resistance just above Monday's close ($38.24), reaching $38.44 and retreated back to the $38.00 area. It was attempting to absorb the news when a wave of sellers attacked the stock around 10:55 a.m. EST.
Following a quick rebound off $34.72, Mylan's stock bounced into the $36.00 handle before coming down to make a new low for the session at $34.27. That marks its lowest level since it bottomed ahead of its FDA approval of first generic approval of Copaxone at $31.84 and leaped to $37.80 the following session.